This post is the second in a series that examines the products liability risks associated with the FDA’s new rule that allows Institutional Review Boards (IRBs) to waive informed consent requirements for certain low-risk clinical trials.
As clinical trial sponsors adapt to the FDA rule change permitting IRB waivers for minimal risk studies, it’s essential to examine the products liability implications that arise when informed consent forms (ICFs) are waived. The ICF often serves as a “warning label” that informs participants of potential risks and shields sponsors from failure-to-warn claims. Without this protective layer, sponsors may find themselves more vulnerable to legal challenges, particularly in the event of adverse outcomes.
The Role of Informed Consent as a Defense Mechanism
Informed consent documents are not merely administrative formalities; they are vital legal tools that serve multiple purposes in clinical trials. One of the most significant roles they play is in mitigating liability risks by ensuring that participants are fully informed of the potential risks and consequences associated with the trial. This transparency is not
The waiver of informed consent, while streamlining the administrative process for minimal risk studies, removes this layer of defense because sponsors continue to owe certain duties under products liability law. FDA regulations may allow for flexibility in obtaining informed consent, but they do not negate the underlying legal duties that exist due to the inherent nature of conducting a clinical trial. The lack of a documented informed consent process can complicate the defense, making it easier for plaintiffs to argue that the sponsor failed to fulfill their duty to warn.
Products Liability Risks Associated with Waiving Informed Consent
Products liability claims often hinge on the adequacy of warnings provided to users, and clinical trial participants are no exception. When sponsors utilize the ICF waiver that will allow certain low-risk trials to proceed without obtaining informed consent from the subjects, sponsors must recognize and prepare for the increased risk of being held liable for failure-to-warn claims. The informed consent document has long served as a crucial component in protecting sponsors from products liability claims by ensuring that participants are fully aware of the risks they are undertaking. Waiving this requirement can significantly increase exposure to legal challenges.
Sponsors must approach the use of IRB waivers with caution, fully understanding the implications for products liability. In the realm of clinical trials, where the stakes are always high, careful consideration of the legal landscape is crucial for the successful and ethical conduct of research.